Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 3/20 | 0.33 |
| ▸ | CCNH | P51946 | 3/20 | 0.33 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.33 |
| ▸ | HAVCR2 | Q8TDQ0 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23529884 | 0.80 | XDH (0.36) | CDK7CCNHMNAT1HAVCR2CCNE1 | |
| SCHEMBL18788176 | 0.80 | LMNA (0.44) | LMNAXBP1 | |
| SCHEMBL18788165 | 0.79 | LMNA (0.38) | LMNAXBP1 | |
| SCHEMBL18510365 | 0.79 | CDK7 (0.34) | CDK7CCNHMNAT1HAVCR2CCNE1 | |
| SCHEMBL24408250 | 0.79 | HAVCR2 (0.35) | CDK7CCNHMNAT1HAVCR2CCNE1 | |
| SCHEMBL18051022 | 0.78 | HTT (0.41) | LMNAXBP1CDK2 | |
| SCHEMBL27223068 | 0.77 | POLB (0.34) | LMNAXBP1 | |
| SCHEMBL21741564 | 0.75 | CDK2 (0.39) | CDK7CCNHMNAT1HAVCR2CCNE1 | |
| SCHEMBL29174858 | 0.74 | HTR2C (0.51) | LMNACDK7CCNHMNAT1CCNE1 | |
| SCHEMBL15238066 | 0.70 | CDK2 (0.32) | CDK7CCNHCCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567345-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| EP-2820020-B1 | PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2820020-B1 | PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-23 | — | — | US | disclosed |
| WO-2013128029-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013128028-A1 | PYRAZOLO - TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN- DEPENDENT KINASE INHINITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2013-09-06 | — | — | WO | disclosed |
| EP-2634190-A1 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors | Lead Discovery Center GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2634189-A1 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors | Lead Discovery Center GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2634189-A1 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors | Lead Discovery Center GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2634190-A1 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors | Lead Discovery Center GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | PAK5, STK35, TESK2 | LMNA 3446/4885XBP1 3544/4885CDK7 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.